NASDAQ:ASLN ASLAN Pharmaceuticals (ASLN) Stock Price, News & Analysis → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free ASLN Stock Alerts $0.43 +0.01 (+1.45%) (As of 12:55 PM ET) Add Compare Share Share Today's Range$0.41▼$0.4350-Day Range$0.40▼$0.6052-Week Range$0.39▼$4.23Volume44,039 shsAverage Volume778,276 shsMarket Capitalization$6.97 millionP/E RatioN/ADividend YieldN/APrice Target$11.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ASLAN Pharmaceuticals alerts: Email Address ASLAN Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,566.7% Upside$11.33 Price TargetShort InterestHealthy1.38% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.55) to ($2.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.39 out of 5 stars 3.5 Analyst's Opinion Consensus RatingASLAN Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageASLAN Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about ASLAN Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.38% of the float of ASLAN Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverASLAN Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ASLAN Pharmaceuticals has recently decreased by 56.85%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldASLAN Pharmaceuticals does not currently pay a dividend.Dividend GrowthASLAN Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASLN. Previous Next 1.9 News and Social Media Coverage News SentimentASLAN Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.Search InterestOnly 1 people have searched for ASLN on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat Follows2 people have added ASLAN Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ASLAN Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.69% of the stock of ASLAN Pharmaceuticals is held by insiders.Percentage Held by Institutions58.82% of the stock of ASLAN Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ASLAN Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ASLAN Pharmaceuticals are expected to grow in the coming year, from ($2.55) to ($2.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ASLAN Pharmaceuticals is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ASLAN Pharmaceuticals is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ASLAN Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTICheck out WFC chartI’m about to go head-to-head with Wall Street… Exposing one of their BEST kept secrets… A secret that they’ve kept hidden in the dark for YEARS… And according to the backtest, it’s already shown the power to pay out… 28%... 41%... Even 83%... Not in a year… Not in a month… But in just 24 hours…You gotta click here because I’m about to show how to spot what could be the next one. About ASLAN Pharmaceuticals Stock (NASDAQ:ASLN)ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.Read More ASLN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASLN Stock News HeadlinesMay 21, 2024 | globenewswire.comASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International ConferenceMay 9, 2024 | globenewswire.comASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | globenewswire.comASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL EventMay 2, 2024 | globenewswire.comASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other BiologicsApril 30, 2024 | globenewswire.comASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to DupilumabApril 24, 2024 | finance.yahoo.comASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International ConferenceApril 22, 2024 | markets.businessinsider.comAslan Announces Positive Results For Phase 2 Study Of Eblasakimab In AD PatientsApril 22, 2024 | globenewswire.comASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis PatientsApril 20, 2024 | finanznachrichten.deASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Announces Receipt of Nasdaq NoticeApril 19, 2024 | globenewswire.comASLAN Pharmaceuticals Announces Receipt of Nasdaq NoticeApril 14, 2024 | finanznachrichten.deASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateApril 12, 2024 | msn.comASLAN Falls On Q4 FiguresApril 12, 2024 | markets.businessinsider.comASLN Stock Earnings: ASLAN Pharma Misses EPS for Q4 2023April 12, 2024 | globenewswire.comASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 27, 2024 | globenewswire.comAslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and DisordersMarch 18, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Urogen Pharma (URGN) and Legend Biotech (LEGN)March 18, 2024 | finance.yahoo.comASLN Apr 2024 5.000 callMarch 17, 2024 | seekingalpha.comWeek In Review: Under Pressure From U.S. Congress, WuXi AppTec Resigns From BIOMarch 14, 2024 | finance.yahoo.comSmart Home Healthcare Market to Reach USD 160.7 Billion by 2032, at 24.3% CAGR: Astute AnalyticaMarch 14, 2024 | finance.yahoo.comREGN May 2024 885.000 callMarch 12, 2024 | msn.comASLAN Pharmaceuticals announces $5M registered direct offeringMarch 12, 2024 | globenewswire.comASLAN Pharmaceuticals Announces $5 Million Registered Direct OfferingMarch 12, 2024 | realmoney.thestreet.comPiper 'confident' partner or buyer will see benefit of Aslan's eblasakimabMarch 11, 2024 | msn.comU.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.12%March 11, 2024 | msn.comBank Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Monday TradingSee More Headlines Receive ASLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ASLAN Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/10/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ASLN CUSIPN/A CIK1722926 Webwww.aslanpharma.com Phone65-6817-9598Fax65-6225-2419Employees35Year FoundedN/APrice Target and Rating Average Stock Price Target$11.33 High Stock Price Target$15.00 Low Stock Price Target$9.00 Potential Upside/Downside+2,598.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,220,000.00 Net MarginsN/A Pretax Margin-290.83% Return on Equity-8,454.87% Return on Assets-121.60% Debt Debt-to-Equity RatioN/A Current Ratio1.05 Quick Ratio1.05 Sales & Book Value Annual Sales$12 million Price / Sales0.57 Cash FlowN/A Price / Cash FlowN/A Book Value($0.81) per share Price / Book-0.52Miscellaneous Outstanding Shares16,350,000Free Float15,583,000Market Cap$6.87 million OptionableOptionable Beta1.44 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Carl Alan Jason Morton Firth EMBA (Age 51)Ph.D., Founder, CEO & Executive Director Mr. Kiran Kumar Asarpota (Age 45)COO & Head of Finance Mr. Ben Goodger (Age 61)General Counsel Mr. Stephen Doyle (Age 51)Chief Business Officer Dr. Alexandre Kaoukhov M.D. (Age 50)Chief Medical Officer Charlie HsuInvestor Relations DirectorChi-Chin WangIR & Corporate Development DirectorMore ExecutivesKey CompetitorsBolt BiotherapeuticsNASDAQ:BOLTSpruce BiosciencesNASDAQ:SPRBNanoViricidesNYSE:NNVCBioVieNASDAQ:BIVIEnlivex TherapeuticsNASDAQ:ENLVView All Competitors ASLN Stock Analysis - Frequently Asked Questions Should I buy or sell ASLAN Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASLAN Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ASLN shares. View ASLN analyst ratings or view top-rated stocks. What is ASLAN Pharmaceuticals' stock price target for 2024? 3 Wall Street analysts have issued 1 year price objectives for ASLAN Pharmaceuticals' shares. Their ASLN share price targets range from $9.00 to $15.00. On average, they anticipate the company's share price to reach $11.33 in the next twelve months. This suggests a possible upside of 2,566.7% from the stock's current price. View analysts price targets for ASLN or view top-rated stocks among Wall Street analysts. How have ASLN shares performed in 2024? ASLAN Pharmaceuticals' stock was trading at $0.5221 on January 1st, 2024. Since then, ASLN shares have decreased by 18.6% and is now trading at $0.4250. View the best growth stocks for 2024 here. Are investors shorting ASLAN Pharmaceuticals? ASLAN Pharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totaling 302,200 shares, a drop of 56.9% from the April 30th total of 700,400 shares. Based on an average daily volume of 1,210,000 shares, the short-interest ratio is currently 0.2 days. Currently, 1.4% of the company's stock are short sold. View ASLAN Pharmaceuticals' Short Interest. When is ASLAN Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our ASLN earnings forecast. How were ASLAN Pharmaceuticals' earnings last quarter? ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) released its quarterly earnings data on Thursday, May, 9th. The company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by $0.61. When did ASLAN Pharmaceuticals' stock split? Shares of ASLAN Pharmaceuticals reverse split on the morning of Monday, March 13th 2023. The 1-5 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of ASLAN Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ASLAN Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Onconova Therapeutics (ONTX), Aldeyra Therapeutics (ALDX), SCYNEXIS (SCYX) and VBI Vaccines (VBIV). When did ASLAN Pharmaceuticals IPO? ASLAN Pharmaceuticals (ASLN) raised $60 million in an initial public offering on Friday, May 4th 2018. The company issued 7,500,000 shares at $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers. Who are ASLAN Pharmaceuticals' major shareholders? ASLAN Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of ASLAN Pharmaceuticals? Shares of ASLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ASLN) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | Sponsored[PDF Inside] Crypto's $1 Trillion 60-Day Boom + New 2024 Profit StrategyThe crypto industry is exploding and Chris Munch just released a new PDF detailing how you can potentially pro...DeFi Distribution | SponsoredTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ASLAN Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share ASLAN Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.